N-Tosyl-5-bromo-4,7-diazaindole

N-Tosyl-5-bromo-4,7-diazaindole 구조식 이미지
카스 번호:
1201186-54-0
상품명:
N-Tosyl-5-bromo-4,7-diazaindole
동의어(영문):
2-BroMo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine;5H-Pyrrolo[2,3-b]pyrazine, 2-bromo-5-[(4-methylphenyl)sulfonyl]-;Upadacitinib Impurity 2;Upadacitinib Impurity 45;N-Tosyl-5-bromo-4,7-diazaindole;Glycerol(Glycerophosphoric acid);3-Bromo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine;2-BROMO-5-(P-TOLYLSULFONYL)-5H-PYRROLO[2,3-B]PYRAZINE;2-bromo-5-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyrazine;2-bromo-5-(4-methylbenzenesulfonyl)-5H-pyrrolo[2,3-b]pyrazine
CBNumber:
CB62470216
분자식:
C13H10BrN3O2S
포뮬러 무게:
352.21
MOL 파일:
1201186-54-0.mol

N-Tosyl-5-bromo-4,7-diazaindole 속성

끓는 점
499.6±55.0 °C(Predicted)
밀도
1.68±0.1 g/cm3(Predicted)
저장 조건
under inert gas (nitrogen or Argon) at 2-8°C
산도 계수 (pKa)
-2.22±0.30(Predicted)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 GHS hazard pictograms P264, P270, P301+P312, P330, P501
H315 피부에 자극을 일으킴 피부부식성 또는 자극성물질 구분 2 경고 GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 눈에 심한 자극을 일으킴 심한 눈 손상 또는 자극성 물질 구분 2A 경고 GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H335 호흡 자극성을 일으킬 수 있음 특정 표적장기 독성 - 1회 노출;호흡기계 자극 구분 3 경고 GHS hazard pictograms
예방조치문구:
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P305+P351+P338 눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

N-Tosyl-5-bromo-4,7-diazaindole C화학적 특성, 용도, 생산

제조 방법

A solution of anhydrous DMF (272 mL) dissolved with 2-bromo-5H-pyrrolo[2,3-b]pyrazine (78.0 g, 394 mmol) was configured. The temperature is maintained at 0-5 °C (within which the subsequent reaction has been maintained), and the solution was droppedly added to the sodium (12.8 g, 532 mmol) anhydrous DMF (543 mL) suspension in the stirred state within 60 minutes. The solution turned brown and the reaction solution was stirred for about 30 min. Then, within 60 minutes, anhydrous DMF (272 mL) dissolved with p-toluenesulfonyl chloride (94.0 g, 492 mmol) was added. After stirring the mixed solution for about 1 h, it was heated to ambient temperature and stirred for about 18 h. Slowly pour the reaction mixture into ice water (6 L) and added 2.5 N NaOH in water (50.0 mL, 125 mmol). Filter the sediment to collect and stirred 3 times with cold water (200 mL). Finally, the collected products were filtered and dried to a constant weight in a vacuum oven at about 55 °C to obtain N-Tosyl-5-bromo-4,7-diazaindole (134.6 g, 97%).
N-Tosyl-5-bromo-4,7-diazaindole

참고 문헌

[1] Yael Ross, Marina Magrey, Use of upadacitinib in the treatment of psoriatic arthritis, Immunotherapy, 2021, 13.
[2] Lina Serhal, Christopher J Edwards, Upadacitinib for the treatment of rheumatoid arthritis, Expert Review of Clinical Immunology, 2018, 15,13-25.
[3] Eleni Kotsiliti, Upadacitinib therapy for Crohn’s disease, Nature Reviews Gastroenterology & Hepatology, 2023, 20, 483.

N-Tosyl-5-bromo-4,7-diazaindole 준비 용품 및 원자재

원자재

준비 용품


N-Tosyl-5-bromo-4,7-diazaindole 공급 업체

글로벌( 162)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Golden Pharma Co., Limited
+undefined18958062155
sales@zjgoldpharm.com China 5905 58
Hangzhou ICH Biofarm Co., Ltd
+undefined8613073685410
sales@ichemie.com China 985 58
Henan Fengda Chemical Co., Ltd
+86-371-86557731 +86-13613820652
info@fdachem.com China 7934 58
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32480 60
Anhui Dexinjia Biopharm Co., Ltd
+86-531-82375818 +86-15064153060
alice@jndxj.com China 309 58
Accela ChemBio Inc.
(+1)-858-699-3322
info@accelachem.com United States 19965 58
Alchem Pharmtech,Inc.
8485655694
sales@alchempharmtech.com United States 63711 58
Shanghai Jinghao Pharmaceutical Co.,Ltd
+86-21-68900963
sales@jinghaopharma.com CHINA 153 58
Shanghai Yingrui Biopharma Co.,Ltd
21-33585366
export01@shyrchem.com CHINA 1320 58
career henan chemical co
+86-0371-86658258 15093356674;
factory@coreychem.com China 29826 58

N-Tosyl-5-bromo-4,7-diazaindole 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved